MyMD still awaiting Phase 2 data for MYMD-1 sarcopenia trial completed June 2023

Q/C TECHNOLOGIES, INC.

Phase 2 trial of MYMD-1 for sarcopenia completed in June 2023; data not received as of July 14.
No guidance on timing of data release; company states it is 'still awaiting receipt.'
No other material updates in this filing; stock trades on Nasdaq under ticker MYMD.

item 8.01

Q/C TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-024537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.